Real-world outcomes in patients with unresected stage III non-small cell lung cancer

Kellie J. Ryan, Karen E. Skinner, Ancilla W. Fernandes, Rajeshwari S. Punekar, Melissa Pavilack, Mark S. Walker, Noam Vanderwalde

Research output: Contribution to journalReview article

Abstract

This study examined real-world clinical outcomes such as progression-free survival (PFS), time to metastasis (TTM), overall survival (OS), and health-related quality of life (HRQOL) in patients with unresected stage III non-small cell lung cancer (NSCLC) treated in the community setting. A retrospective review of medical records extracted from 10 US community oncology practices was conducted. Eligible patients were adults diagnosed with stage III NSCLC from 1/1/2011 to 3/1/2016 without evidence of surgical resection within 6 months after stage III NSCLC diagnosis (index date). PFS, OS, and TTM were assessed from the index date, and were analyzed using Kaplan–Meier and Cox regression analyses. HRQOL was assessed for a subset of patients using a patient-reported measure, the 86-item Patient Care Monitor (PCM). Linear mixed models (LMM) were used to assess the impact of patient characteristics and change in PCM scores associated with progression. Among the sample of 478 patients, median PFS (95% confidence interval) was 10 months (9–11), median OS was 20 months (17–22), and median TTM was 30 months (23–45). Most patients (58.2%) experienced disease progression, which the LMM showed to be associated with significant worsening of physical symptoms and psychological states (p < 0.001). This study documented PFS and OS consistent with published literature. The majority of patients experienced disease progression, which was associated with worsening of HRQOL. These findings highlighted the need for better therapeutic options in patients with unresected stage III NSCLC with potential to improve patient outcomes and HRQOL.

Original languageEnglish (US)
Article number24
JournalMedical Oncology
Volume36
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Quality of Life
Survival
Neoplasm Metastasis
Disease Progression
Linear Models
Patient Care
Medical Records
Regression Analysis
Confidence Intervals
Psychology

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ryan, K. J., Skinner, K. E., Fernandes, A. W., Punekar, R. S., Pavilack, M., Walker, M. S., & Vanderwalde, N. (2019). Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Medical Oncology, 36(3), [24]. https://doi.org/10.1007/s12032-019-1249-1

Real-world outcomes in patients with unresected stage III non-small cell lung cancer. / Ryan, Kellie J.; Skinner, Karen E.; Fernandes, Ancilla W.; Punekar, Rajeshwari S.; Pavilack, Melissa; Walker, Mark S.; Vanderwalde, Noam.

In: Medical Oncology, Vol. 36, No. 3, 24, 01.03.2019.

Research output: Contribution to journalReview article

Ryan, KJ, Skinner, KE, Fernandes, AW, Punekar, RS, Pavilack, M, Walker, MS & Vanderwalde, N 2019, 'Real-world outcomes in patients with unresected stage III non-small cell lung cancer', Medical Oncology, vol. 36, no. 3, 24. https://doi.org/10.1007/s12032-019-1249-1
Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS et al. Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Medical Oncology. 2019 Mar 1;36(3). 24. https://doi.org/10.1007/s12032-019-1249-1
Ryan, Kellie J. ; Skinner, Karen E. ; Fernandes, Ancilla W. ; Punekar, Rajeshwari S. ; Pavilack, Melissa ; Walker, Mark S. ; Vanderwalde, Noam. / Real-world outcomes in patients with unresected stage III non-small cell lung cancer. In: Medical Oncology. 2019 ; Vol. 36, No. 3.
@article{c086883bfebd478580936a184b712513,
title = "Real-world outcomes in patients with unresected stage III non-small cell lung cancer",
abstract = "This study examined real-world clinical outcomes such as progression-free survival (PFS), time to metastasis (TTM), overall survival (OS), and health-related quality of life (HRQOL) in patients with unresected stage III non-small cell lung cancer (NSCLC) treated in the community setting. A retrospective review of medical records extracted from 10 US community oncology practices was conducted. Eligible patients were adults diagnosed with stage III NSCLC from 1/1/2011 to 3/1/2016 without evidence of surgical resection within 6 months after stage III NSCLC diagnosis (index date). PFS, OS, and TTM were assessed from the index date, and were analyzed using Kaplan–Meier and Cox regression analyses. HRQOL was assessed for a subset of patients using a patient-reported measure, the 86-item Patient Care Monitor (PCM). Linear mixed models (LMM) were used to assess the impact of patient characteristics and change in PCM scores associated with progression. Among the sample of 478 patients, median PFS (95{\%} confidence interval) was 10 months (9–11), median OS was 20 months (17–22), and median TTM was 30 months (23–45). Most patients (58.2{\%}) experienced disease progression, which the LMM showed to be associated with significant worsening of physical symptoms and psychological states (p < 0.001). This study documented PFS and OS consistent with published literature. The majority of patients experienced disease progression, which was associated with worsening of HRQOL. These findings highlighted the need for better therapeutic options in patients with unresected stage III NSCLC with potential to improve patient outcomes and HRQOL.",
author = "Ryan, {Kellie J.} and Skinner, {Karen E.} and Fernandes, {Ancilla W.} and Punekar, {Rajeshwari S.} and Melissa Pavilack and Walker, {Mark S.} and Noam Vanderwalde",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s12032-019-1249-1",
language = "English (US)",
volume = "36",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Real-world outcomes in patients with unresected stage III non-small cell lung cancer

AU - Ryan, Kellie J.

AU - Skinner, Karen E.

AU - Fernandes, Ancilla W.

AU - Punekar, Rajeshwari S.

AU - Pavilack, Melissa

AU - Walker, Mark S.

AU - Vanderwalde, Noam

PY - 2019/3/1

Y1 - 2019/3/1

N2 - This study examined real-world clinical outcomes such as progression-free survival (PFS), time to metastasis (TTM), overall survival (OS), and health-related quality of life (HRQOL) in patients with unresected stage III non-small cell lung cancer (NSCLC) treated in the community setting. A retrospective review of medical records extracted from 10 US community oncology practices was conducted. Eligible patients were adults diagnosed with stage III NSCLC from 1/1/2011 to 3/1/2016 without evidence of surgical resection within 6 months after stage III NSCLC diagnosis (index date). PFS, OS, and TTM were assessed from the index date, and were analyzed using Kaplan–Meier and Cox regression analyses. HRQOL was assessed for a subset of patients using a patient-reported measure, the 86-item Patient Care Monitor (PCM). Linear mixed models (LMM) were used to assess the impact of patient characteristics and change in PCM scores associated with progression. Among the sample of 478 patients, median PFS (95% confidence interval) was 10 months (9–11), median OS was 20 months (17–22), and median TTM was 30 months (23–45). Most patients (58.2%) experienced disease progression, which the LMM showed to be associated with significant worsening of physical symptoms and psychological states (p < 0.001). This study documented PFS and OS consistent with published literature. The majority of patients experienced disease progression, which was associated with worsening of HRQOL. These findings highlighted the need for better therapeutic options in patients with unresected stage III NSCLC with potential to improve patient outcomes and HRQOL.

AB - This study examined real-world clinical outcomes such as progression-free survival (PFS), time to metastasis (TTM), overall survival (OS), and health-related quality of life (HRQOL) in patients with unresected stage III non-small cell lung cancer (NSCLC) treated in the community setting. A retrospective review of medical records extracted from 10 US community oncology practices was conducted. Eligible patients were adults diagnosed with stage III NSCLC from 1/1/2011 to 3/1/2016 without evidence of surgical resection within 6 months after stage III NSCLC diagnosis (index date). PFS, OS, and TTM were assessed from the index date, and were analyzed using Kaplan–Meier and Cox regression analyses. HRQOL was assessed for a subset of patients using a patient-reported measure, the 86-item Patient Care Monitor (PCM). Linear mixed models (LMM) were used to assess the impact of patient characteristics and change in PCM scores associated with progression. Among the sample of 478 patients, median PFS (95% confidence interval) was 10 months (9–11), median OS was 20 months (17–22), and median TTM was 30 months (23–45). Most patients (58.2%) experienced disease progression, which the LMM showed to be associated with significant worsening of physical symptoms and psychological states (p < 0.001). This study documented PFS and OS consistent with published literature. The majority of patients experienced disease progression, which was associated with worsening of HRQOL. These findings highlighted the need for better therapeutic options in patients with unresected stage III NSCLC with potential to improve patient outcomes and HRQOL.

UR - http://www.scopus.com/inward/record.url?scp=85060877434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060877434&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1249-1

DO - 10.1007/s12032-019-1249-1

M3 - Review article

C2 - 30706218

AN - SCOPUS:85060877434

VL - 36

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

M1 - 24

ER -